Reuters logo
4 个月前
BRIEF-Chemocentryx receives FDA orphan drug designation for Avacopan in treatment of debilitating kidney disease
2017年3月22日 / 下午12点47分 / 4 个月前

BRIEF-Chemocentryx receives FDA orphan drug designation for Avacopan in treatment of debilitating kidney disease

1 分钟阅读

March 22 (Reuters) - Chemocentryx Inc

* Chemocentryx receives fda orphan drug designation for avacopan in the treatment of debilitating kidney disease c3 glomerulopathy (c3g)

* Chemocentryx inc says plans to initiate a multi-center clinical endpoint study of avacopan for treatment of c3g in first half of 2017

* Chemocentryx inc - u.s. Fda has granted orphan drug designation for avacopan in treatment of patients with c3 glomerulopathy (c3g) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below